Delius Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 9.90 M
as on 19-12-2024
- Paid Up Capital ₹ 6.50 M
as on 19-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 163.17%
(FY 2022)
- Profit 35.41%
(FY 2022)
- Ebitda -16.49%
(FY 2022)
- Net Worth 28.06%
(FY 2022)
- Total Assets 23.01%
(FY 2022)
About Delius Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.90 M and a paid-up capital of Rs 6.50 M, as per Ministry of Corporate Affairs (MCA) records.
Digvijay Shrivastawa and Sapna Srivastwa serve as directors at the Company.
- CIN/LLPIN
U24232DL2014PTC270434
- Company No.
270434
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Delius Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Digvijay Shrivastawa  | Director | 14-Aug-2014 | Current |
| Sapna Srivastwa | Director | 24-Apr-2016 | Current |
Financial Performance of Delius Pharmaceuticals.
Delius Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 163.17% increase. The company also saw a substantial improvement in profitability, with a 35.41% increase in profit. The company's net worth Soared by an impressive increase of 28.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delius Pharmaceuticals?
In 2023, Delius Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Delius Pharmaceuticals?
Delius Pharmaceuticals has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delius Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delius Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
